WuXi Biologics ISIN: KYG970081173 Forum: Aktien User: Summer.76

China Biotech Rout Shows Growing Pain From US Decoupling Drive • US efforts to boost biotech industry lead to China selloff • Traders say bilateral tensions may see more sectors targeted https://www.bloomberg.com/news/articles/2022-09-13/china-biotech-rout-shows-growing-pain-from-us-decoupling-drive?srnd=premium-europe The latest US effort to reduce reliance on China is striking hard at the Asian nation’s biotech stocks, as investors price in more indications of decoupling between the world’s two biggest economies.    ... The key question facing traders now is which sector will be the next to be targeted by American officials.  The US “could move the sanctions down along the supply chain in the areas that’s already sanctioned, such as semiconductor and biotech segments,” said Dai Ming, Shanghai-based fund manager at Huichen Asset Management. It may also target areas that may threaten US position, such as new energy and AI-related industries, he said.  ...

Moonshot Weighs On Wuxi While Nio Fans Rejoice In ET5 Launch https://www.forbes.com/sites/brendanahern/2022/09/13/moonshot-weighs-on-wuxi-while-nio-fans-rejoice-in-et5-launch/ ... Hong Kong and Chinese biotech stocks were hit hard after President Biden’s Cancer Research "Moonshot" initiative was launched, presenting the potential for onshoring contract research that is currently done by Chinese firms. The initiative aims to find a cure for cancer by growing the US biotech industry, which investors took as a negative for Chinese biotech and healthcare companies. Wuxi Biologics (2269 HK) was Hong Kong’s most heavily traded stock by value today, falling -19.94% while WuXiAppTec (2359 HK) fell -16.82% as investors shot first before asking questions. Big companies like Wuxi already have significant operations in the United States so the reaction feels overdone. ...

Morgen bestimmt positiv

Was Denkt ihr! Jetzt Nachkaufen oder noch 1-2Tage warten?

Heute zerreißt es sie ja förmlich. Ich hoffe es ist nicht von Dauer

After the Hang Seng Index fell 63 points, it rose 109 points and WuXi decimated 20% https://m.hkej.com/landing/mobarticle2?id=3245272 ... Foreign sources quoted news that US President Biden is about to sign a new executive order to expand US bio-manufacturing to reduce dependence on China. The pharmaceutical outsourcing service industry (CXO) was sold out across the board this morning. ....

https://finance.sina.cn/hkstock/sckxjfx/2022-09-09/detail-imqqsmrn8424147.d.html?from=wap

WuXi Biologics Announces GMP Release of Its First North American Biomanufacturing Facility in Cranbury, New Jersey https://www.prnewswire.co.uk/news-releases/wuxi-biologics-announces-gmp-release-of-its-first-north-american-biomanufacturing-facility-in-cranbury-new-jersey-819520512.html

http://www.takungpao.com/finance/236135/2022/0823/756604.html Share Screening

Lyon: Maintain "Outperform" rating on WuXi Biologics (02269), target price raised to HK$84 https://finance.sina.cn/hkstock/ggpj/2022-08-22/detail-imizmscv7204955.d.html?from=wap

"Research Report" Goldman Sachs downgrades WuXi Biologics (02269.HK) earnings forecast to reflect slightly lower gross profit rating "Buy http://www.aastocks.com/tc/stocks/news/aafn-news/NOW.1206110/3

Zhongtai Securities: Maintain "Buy" rating on WuXi Biologics (02269); capacity expansion to accelerate commercialization projects is expected to continue https://hk.investing.com/news/stock-market-news/article-249098

Essence Securities: Rating WuXi Biologics (02269) "Buy-A" to Achieve High Growth in 22H1 https://finance.sina.cn/hkstock/ggpj/2022-08-19/detail-imizirav8789043.d.html?from=wap

WuXi Biologics (02269) Subsidiary WuXi XDC Granted a Total of 9,052,800 Share Options https://finance.sina.cn/hkstock/gsxw/2022-08-18/detail-imizirav8726980.d.html?from=wap

http://www.aastocks.com/tc/stocks/news/aafn-news/NOW.1205548/1

WuXi Biologics Reports Strong 2022 Interim Results https://www.prnewswire.com/news-releases/wuxi-biologics-reports-strong-2022-interim-results-301607649.html Revenue Increased by 63.5% Y-o-Y to RMB7,206.4 Million Gross Profit Increased by 48.6% Y-o-Y to RMB3,413.2 Million Net Profit Grew by 39.2% Y-o-Y to RMB2,621.2 Million Adjusted Net Profit Rose by 60.9% to RMB2,914.9 Million Total Backlog Reached US$18,467 Million ...